source
- Alkermes reports early proof-of-concept for orexin-2 drug in ADHDAlkermes announced early-stage trial results for ALKS 7290, an orexin‑2 receptor agonist originally being developed for narcolepsy, showing proof of concept in ADHD. The study reported dose‑depend…
- Roche’s enicepatide shows dose-dependent blood sugar and weight loss in Phase 2 diabetes trialRoche reported that its injectable GLP-1/GIP dual agonist enicepatide, acquired through the Carmot Therapeutics purchase, achieved reductions in blood glucose and body weight in a Phase 2 study of…